The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

Kaiser-Guignard, Julie; Canellini, Giorgia; Lion, Niels; Abonnenc, Mélanie; Osselaer, Jean-Claude; Tissot, Jean‐Daniel

doi:10.1016/j.blre.2014.07.005

Cited by 97 publications

(116 citation statements)

References 86 publications

(97 reference statements)

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Our regional blood transfusion services usually have a mix of both types of PC in order to optimize the use of whole blood donations, to mitigate the risk of shortages, and to ensure adequate availability of HLA-typed AP-PC. Since the introduction of mandatory universal pathogen inactivation of all PC in 2011 [2], AP-PC and BC-PC are considered clinically equivalent. However, some differences exist between both types of PC, such as the extent of residual contaminating red blood cells (RBC), which has been shown to be considerably lower for AP-PC (0.00017-0.009 ml) compared to BC-PC (0.036-0.59 ml) [3,4,5,6,7,8].…”

Section: Introductionmentioning

confidence: 99%

Platelet Transfusion Induces Alloimmunization to D and Non-D Rhesus Antigens

Reckhaus

Jutzi

Fontana

et al. 2018

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Platelet concentrates (PC) contain residual contaminating red blood cells (RBC), being higher in pooled buffy coat PC (BC-PC) than in apheresis units (AP-PC). Data about PC-induced alloimmunization against non-D Rhesus (Rh) antigens are limited. Methods: For all newly detected RhD and non-D alloantibodies between August 2015 and September /2017 we prospectively evaluated if they were triggered through PC by analyzing for incompatible RBC and/or PC transfusions. Results: We found 5,799 positive results in 89,190 antibody screening tests. We identified 13 newly detectable Rh antibodies through incompatible PCs in 11 patients: 6× anti-D, 4× anti-E, 2× anti-c, 1× anti-f. They received a total of 156 PC (83 BC-PC; 73 AP-PC): 5 patients received incompatible BC-PC only, 1 patient received incompatible AP-PC only, 5 patients received incompatible BC-PC and AP-PC. Quality control showed a mean (range) of 0.304 (0.152-1.662) and 0.014 (0.003-0.080) × 10⁹ RBC/l for BC-PC and AP-PC, respectively. Ten of the 11 patients received RBC transfusions, all of them being antigen-negative for the alloantibodies identified. Conclusions: PC transfusions may not only induce RhD alloimmunization, but also immunization against further Rh antigens such as c, E, and f. The risk seems higher for BC-PC than for AP-PC. The results may have impact on future recommendations of PC transfusion with respect to Rh compatibility and upper limits of RBC contamination.

show abstract

Section: Introductionmentioning

confidence: 99%

Platelet Transfusion Induces Alloimmunization to D and Non-D Rhesus Antigens

Reckhaus

Jutzi

Fontana

et al. 2018

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…Because there is a risk of bacterial growth during RT storage, as well as the danger of other emerging (undetected) pathogens, several countries now use pathogen inactivation technologies (PITs) to ensure a safer product [5]. Indeed, since the introduction of PITs adverse transfusion reactions and transfusion-transmitted infections have decreased dramatically [6]. Currently, there are two main commercially available PITs: INTERCEPT™ (Cerus, Concord, MA, USA) and Mirasol ® (Terumo BCT, Lakewood, CO, USA).…”

Section: Introductionmentioning

confidence: 99%

Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion

Sonego

Abonnenc

Tissot

et al. 2017

IJMS

Self Cite

View full text Add to dashboard Cite

Blood banks use pathogen inactivation (PI) technologies to increase the safety of platelet concentrates (PCs). The characteristics of PI-treated PCs slightly differ from those of untreated PCs, but the underlying reasons are not well understood. One possible cause is the generation of oxidative stress during the PI process. This is of great interest since reactive oxygen species (ROS) act as second messengers in platelet functions. Furthermore, there are links between protein oxidation and phosphorylation, another mechanism that is critical for cell regulation. Current research efforts focus on understanding the underlying mechanisms and identifying new target proteins. Proteomics technologies represent powerful tools for investigating signaling pathways involving ROS and post-translational modifications such as phosphorylation, while quantitative techniques enable the comparison of the platelet resting state versus the stimulated state. In particular, redox cysteine is a key player in platelet activation upon stimulation by different agonists. This review highlights the experiments that have provided insights into the roles of ROS in platelet function and the implications for platelet transfusion, and potentially in diseases such as inflammation and platelet hyperactivity. The review also describes the implication of redox mechanism in platelet storage considerations.

show abstract

“…Published hemovigilance data predominantly concern the A-L (Intercept) method with all reports confirming both the safety and efficacy of A-L-treated platelets in a huge number of platelet transfusions. 312 If on the one hand, PR technologies are designed to irreversibly disrupt nucleic acids of pathogens, on the other, they also cause collateral reactive oxidation-related damage to platelet proteins, thus enhancing the platelet storage lesion. Comparison of such damage by different PR techniques has been shown by a consortium represented by four (Switzerland, Italy, France, Germany) European research groups, along with a Canadian group.…”

Section: European Research Contributionsmentioning

confidence: 99%

The European Hematology Association Roadmap for European Hematology Research: a consensus document

et al. 2016

View full text Add to dashboard Cite

T he European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.

show abstract

The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

Cited by 97 publications

References 86 publications

Platelet Transfusion Induces Alloimmunization to D and Non-D Rhesus Antigens

Platelet Transfusion Induces Alloimmunization to D and Non-D Rhesus Antigens

Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion

The European Hematology Association Roadmap for European Hematology Research: a consensus document

Contact Info

Product

Resources

About